Fecal Microbial Transplantation in Severe Alcoholic Hepatitis

NCT ID: NCT04758806

Last Updated: 2022-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. A subtype of Alcoholic hepatitis (AH), named severe alcoholic hepatitis (SAH) is associated with high short-term mortality (J Hepatol, 2019)
2. The only SAH treatment option - corticosteroids (CS) - are often contraindicated or ineffective (STOPAH Trial)
3. New treatment modalities for remaining patients are much needed
4. Fecal microbial transplantation (FMT) is one of the promising therapies
5. Investigators aimed to see if FMT improves survival in patients admitted with SAH, not responding to-, or non-eligible for CS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* FMT via upper GI tract is provided to CS non-responders (NR) or non-eligible (NE) adult patients hospitalized with SAH (determined by the Lille-model).
* Modified version of the Sarin FMT protocol is used with microbiota material procured from unrelated healthy donors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholic Hepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Eligible for the study are consecutive consenting adult patients
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fecal microbial transplantation from unrelated donor

Fecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days

Group Type EXPERIMENTAL

Fecal microbial transplantation

Intervention Type BIOLOGICAL

Procured faeces procured from unrelated donor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fecal microbial transplantation

Procured faeces procured from unrelated donor

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* consenting, adult
* severe form of acute alcoholic hepatitis (SAH)
* non-responder to corticosteroids according to the Lille model
* patients with SAH not eligible for corticosteroids based on their contraindications

Exclusion Criteria

* active infection
* presence of untreated large / high-risk / bleeding esophageal varices
* too sick for any therapy / futility (chronic extrahepatic organ failures, no potential for recovery, etc)
* malignancy except for hepatocellular carcinoma in Milan criteria
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ľubomír Skladaný MD, PhD

Head, Department of Internal Medicine and HEGITO Liver Unit, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lubomir Skladany, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Head Dept Internal Medicine F.D.Roosevelt Teaching Hospital Banska Bystrica Slovakia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

F.D.Roosevelt Teaching Hospital

Banská Bystrica, , Slovakia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lubomir Skladany, MD,PhD

Role: CONTACT

+421905482997

Natalia Bystrianska, MD

Role: CONTACT

+421917944393

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lubomir Skladany, MD, PhD

Role: primary

+421905482997

Natalia Bystrianska, MD

Role: backup

+421917944393

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

432/2018-IK

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Faecal Microbiota Transplantation for Liver Cirrhosis
NCT04932577 RECRUITING PHASE2/PHASE3